ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252 patients.
Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report
Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual Report.
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian market
Telix and SHINE partner for Lutetium-177 Supply
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for lutetium-177
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
Telix announces a global clinical supply agreement with Eckert & Ziegler for lutetium-177
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its objectives
Darren Smith Joins Telix as Deputy Group Chief Financial Officer
Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer.
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot markets.
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic program.
Telix Completes A$175 Million Placement and Launches A$25 Million SPP
Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25 million.